Inimmune has developed a family of next generation TLR agonists designed for optimal safety, activity, delivery, and stability. Our novel compounds are designed to target specific innate immune pathways to reprogram the immune system and drive a therapeutic response. Our lead clinical program is INI-4001 a TLR7/8 agonist, to treat solid tumors that will be completing a Phase I clinical trial in cancer patients by Q4 of 2026. In addition, Inimmune is developing INI-2004, a TLR4 agonist, into a novel, safe, and effective immunotherapy to treat allergic disease with a focus on food allergies. We have successfully completed a Phase I trial with INI-2004 for seasonal allergic rhinitis and are now expanding to treat peanut allergies via sublingual administration.
Inimmune has an ongoing Phase I clinical trial evaluating the safety and tolerability of INI-4001 (a TLR7/8 agonist) as a cancer treatment. NCT06302426 (linked to https://clinicaltrials.gov/study/NCT06302426)
Inimmune has completed a Phase I clinical trial evaluating the safety and tolerability of INI-2004 (a TLR4 agonist) as a treatment for allergic rhinitis. NCT06038279 (linked to https://clinicaltrials.gov/study/NCT06038279)
Based on the promising data from our Phase I allergy trial we are advancing INI-2004 into a Phase I food allergy trial via sublingual administration.
